高级检索
当前位置: 首页 > 详情页

The value of microRNA-21 as a biomarker for the prognosis of lung cancer: A protocol for systematic review and meta-analysis.

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/School of Medicine, University of Electronic Science and Technology of China [b]Department of Medical Oncology, West China fourth hospital of Sichuan University, chendu, P. R. China.
出处:
ISSN:

关键词: lung cancer meta-analysis miRNA-21 prognosis

摘要:
More and more studies are investigating the influence of the expression of MicroRNA-21 (miRNA-21) on prognosis and clinical significance in patients with lung cancer, but the results are contradictory and uncertain. A meta-analysis was conducted with controversial data to accurately assess the issue.A detailed search of relevant research in Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, Web of Science and other databases. Two reviewers independently conducted data extraction and literature quality evaluation. Odd ratio and its 95% confidence intervals were used to evaluate the relationship between miRNA-21 and clinicopathological characteristics of lung cancer patients. Hazard ratios and its 95% confidence intervals To assess the prognostic effect of miRNA-21 on overall survival and disease-free survival. Meta analysis was performed using RevMan 5.3 and Stata 14.0 software.This study will provide a high-quality evidence-based medical evidence of the correlations between miRNA-21 expression and overall survival, disease-free survival and clinicopathological features.The study will provide updated evidence to evaluate whether the expression of miRNA-21 is in association with poor prognosis in patients with lung cancer.The private information from individuals will not publish. This systematic review also will not involve endangering participant rights. Ethical approval is not available. The results may be published in a peer- reviewed journal or disseminated in relevant conferences.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
JCR分区:
出版当年[2020]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q2 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [a]Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/School of Medicine, University of Electronic Science and Technology of China
通讯作者:
通讯机构: [a]Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/School of Medicine, University of Electronic Science and Technology of China [*1]No.55, section 4, South Renmin Road, Chengdu China. Department of Medical Oncology, Sichuan Cancer Hospital & Institute/Sichuan Cancer Center/School of Medicine, University of Electronic Science and Technology of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号